Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | RARA | P10276 | 5/20 | 0.34 |
| ▸ | RARB | P10826 | 5/20 | 0.34 |
| ▸ | RARG | P13631 | 5/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19804300 | 0.96 | POLB (0.35) | CA1CA2POLBAPEX1HTT | |
| SCHEMBL19804411 | 0.94 | POLB (0.37) | CA1CA2POLBAPEX1HTT | |
| SCHEMBL19804316 | 0.94 | CA1 (0.38) | CA1CA2POLBAPEX1HTT | |
| SCHEMBL19804408 | 0.93 | POLB (0.36) | CA1CA2POLBAPEX1HTT | |
| SCHEMBL19804054 | 0.92 | TDP1 (0.41) | CA1CA2POLBAPEX1HTT | |
| SCHEMBL19804043 | 0.91 | ESR2 (0.36) | CA1CA2SLC2A1RARARARB | |
| SCHEMBL19804323 | 0.91 | RARA (0.37) | CA1CA2POLBAPEX1HTT | |
| SCHEMBL19804449 | 0.89 | PTGS1 (0.36) | CA1CA2POLBAPEX1HTT | |
| SCHEMBL19804337 | 0.88 | RARB (0.39) | CA1CA2POLBAPEX1HTT | |
| SCHEMBL19796597 | 0.88 | RARB (0.46) | RARARARBRARGTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | CA1 489/4885CA2 2120/4885POLB 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.